Nebido is a brand name for the drug testosterone undecanoate, which is a type of androgen hormone. It is a clear, slightly yellowish oily solution for injection and is supplied in vials.
Each vial of Nebido contains 1000 mg of testosterone undecanoate as the active ingredient, along with benzyl benzoate and castor oil.
Nebido is primarily used for the treatment of male hypogonadism, a condition in which the male body does not produce enough testosterone. It is also indicated for the treatment of transgender women undergoing hormone therapy as part of gender reassignment.
Usage and Dosage:
Nebido should be administered only under the supervision of a qualified healthcare professional who is well-versed in the use of androgen hormones. The recommended dosage typically depends on the patient’s medical history, current hormonal status, and other relevant factors.
For male hypogonadism, the recommended dose of Nebido is 1000 mg administered through intramuscular injection every 10 to 14 weeks. The treatment may continue for an extended duration to maintain optimal testosterone levels. The injection site should be alternated between the left and right buttock muscles.
For transgender women, the dose of Nebido may vary, but generally, a lower dose of 250-500 mg is administered every 2-4 weeks.
Nebido should be stored at room temperature (15-25°C or 59-77°F) in its original container until use. Prolonged exposure to light should be avoided. Unused portions of the vial should not be saved for future use.
Mechanism of Action:
Nebido works by increasing the levels of testosterone in the body, resulting in the development and maintenance of male sexual characteristics, including the growth and maintenance of the prostate, seminal vesicles, penis, and scrotum. It also stimulates the growth of bone and muscle mass, and red blood cell production.
Nebido is contraindicated in patients with a known hypersensitivity to testosterone undecanoate or any of the other ingredients in the formulation. It should not be used in women, especially during pregnancy and breastfeeding, as it may cause fetal harm and masculinization of the female fetus. Nebido should also be avoided by patients with prostate or breast cancer.
Nebido may interact with other medicines, causing adverse effects. Patients must inform their doctor if they are taking any prescription or over-the-counter medicines, herbal remedies, or dietary supplements before starting treatment with Nebido.
The common side effects observed with Nebido include acne, mood swings, headache, nausea, hot flushes, increased blood pressure, hair loss, and injection site pain and swelling. Serious side effects such as blood clots, liver damage, and prostate cancer can also occur, but they are rare.
In conclusion, Nebido is a powerful androgen hormone replacement therapy drug used to treat male hypogonadism and transgender hormone therapy. It should be used only under the supervision of a doctor and following his prescribed dosage. Patients should be monitored closely for side effects and report them to their healthcare provider immediately.